Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Teijin Pharma presents novel CaSR antagonists with promising in vivo activity

Oct. 16, 2012

Novel GPR119 receptor agonists prepared by Boehringer Ingelheim and Neurocrine Biosciences

Oct. 15, 2012

Roche synthesizes new HSL inhibitors

Oct. 15, 2012

Zafgen presents novel MetAP 2 inhibitors for obesity

Oct. 11, 2012

Significant reduction of HbA1c seen with VRS-859 in clinical trial

Oct. 11, 2012

Phase I and II data presented for semaglutide

Oct. 11, 2012

Ajinomoto to study nateglinide in combination with DPP IV inhibitor

Oct. 10, 2012

European Commission approves Bayer Healthcare's Flexyess

Oct. 10, 2012

FDA reclassifies clinical hold status for Proellex clinical program

Oct. 10, 2012

Asterion patents new fusion proteins for GH disorders

Oct. 10, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...